Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest in a new entity,

The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 million upfront payment – to develop a radioligand therapy (RLT) for rare neuroendocrine tumours (NETs) called AlphaMedix (212Pb-dotamtate).

Sanofi SNY announced that it has entered into an agreement with France-based cancer biotech Orano Med to jointly develop next-generation radioligand therapies for treating rare cancers.Radioligand therapy is a type of precision cancer treatment that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle).

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, Sanofi has returned with 300 million euros ($326 million) to set up a more | The new entity,

Sanofi has partnered with Orano Med, a subsidiary of Orano Group, to develop radioligand therapies for rare cancers. Sanofi will invest €300 million for a 16% stake in the venture. The collaboration focuses on using lead-212 isotopes to target difficult-to-treat cancers.